ACTRN12623000835640
Not yet recruiting
未知
A Phase II Randomised Crossover Trial to Assess Feasibility of Domiciliary Nasal High Flow for Chronic Breathlessness in People with Interstitial Lung Disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Alfred Health
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •oAge 18 years and over
- •oconfirmed ILD as determined by:
- •oradiological evidence on CT chest scan (within last 5 years) or
- •opulmonary function tests with DLco less than 60% and/or restrictive spirometry (within last 3 years)
- •ophysician confirmed optimisation of treatment of ILD
- •obreathlessness as determined by modified medical research council dyspnea score (mMRC) greater than on equal to 2
- •onot currently on home, long\-term, oxygen therapy for greater than or equal to 16h/day and not meeting criteria for home long\-term oxygen therapy (i.e., SpO2 at rest greater than or equal to 92%)
- •opatients using only portable oxygen therapy on exertion remain eligible
- •oable to provide written informed consent
- •ocapable of completing assessments and following the study procedures.
Exclusion Criteria
- •oAcute exacerbation of ILD, including but not limited to:
- •ochest infection in the past 4 weeks (unstable)
- •oon home long\-term oxygen therapy for greater than or equal to 16h/day
- •oenrolled in other clinical trials which may impact breathlessness (as determined by the study investigator)
- •ocommenced (or required to commence during the trial) new treatment for ILD, including but not limited to, anti\-fibrotic, opioids or benzodiazepines in the last 14 days
- •oprevious adverse reaction to NHF
- •oclinician predicted survival less than or equal to 3 months
- •opregnant or breast feeding
- •ocurrent alcoholism or drug abuse
- •ountreated pneumothorax
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Trial with immunotherapie for patients with locally advanced head and neck cancerON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCCMedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-003175-22-DECharite Universitätsmedizin Berlin66
Recruiting
Not Applicable
Effects of replacing the mask on facial bacterial growth and skin physiology in nursesJPRN-UMIN000053450Fujita Health University14
Active, not recruiting
Phase 2
High powered ultrasound to treat pancreas cancerocally advanced pancreatic cancerCancerMalignant neoplasm of pancreasISRCTN56087634niversity of Oxford20
Active, not recruiting
Phase 1
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphomaRelapsed/refractory B-cell non-Hodgkin lymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-003272-13-NLCellPoint B.V.45
Active, not recruiting
Phase 1
A study evaluating the safety and efficacy of 19CP02 in subjects with non-Hodgkin lymphomaEUCTR2021-003272-13-BECellPoint B.V.45